ANI Strikes Deal With Coeptis For Seven Development-Stage Assets
Continuing its acquisition streak, ANI Pharmaceuticals has bought a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments.
You may also be interested in...
Having swelled its pipeline of US injectable drugs through an acquisition, ANI Pharmaceuticals is on the lookout for attractive manufacturing assets.
US niche generics and brands player ANI Pharmaceuticals intends to keep using its cash flow to fund product acquisitions and partnerships, particularly in the injectables arena.
A strong tailwind from antipsychotic drug Vraylar helped Hungary’s Gedeon Richter to post a 40% leap in 2019 net profit. Analysts see more upside ahead for eastern Europe’s largest drugmaker.